UA76969C2 - Lactams and their pharmaceutical use - Google Patents

Lactams and their pharmaceutical use Download PDF

Info

Publication number
UA76969C2
UA76969C2 UA2003055026A UA2003055026A UA76969C2 UA 76969 C2 UA76969 C2 UA 76969C2 UA 2003055026 A UA2003055026 A UA 2003055026A UA 2003055026 A UA2003055026 A UA 2003055026A UA 76969 C2 UA76969 C2 UA 76969C2
Authority
UA
Ukraine
Prior art keywords
substituent
group
acyl
alkyl
carbamoyl
Prior art date
Application number
UA2003055026A
Other languages
English (en)
Ukrainian (uk)
Original Assignee
Ajinomoto Kk
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ajinomoto Kk filed Critical Ajinomoto Kk
Publication of UA76969C2 publication Critical patent/UA76969C2/uk

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/55131,4-Benzodiazepines, e.g. diazepam or clozapine
    • A61K31/55171,4-Benzodiazepines, e.g. diazepam or clozapine condensed with five-membered rings having nitrogen as a ring hetero atom, e.g. imidazobenzodiazepines, triazolam
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/554Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one sulfur as ring hetero atoms, e.g. clothiapine, diltiazem
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/02Drugs for disorders of the nervous system for peripheral neuropathies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D243/00Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms
    • C07D243/06Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4
    • C07D243/10Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D513/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Ophthalmology & Optometry (AREA)
  • Urology & Nephrology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Child & Adolescent Psychology (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Cephalosporin Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Pyrrole Compounds (AREA)
UA2003055026A 2000-12-01 2001-11-29 Lactams and their pharmaceutical use UA76969C2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2000367175 2000-12-01
PCT/JP2001/010435 WO2002044180A1 (en) 2000-12-01 2001-11-29 Lactam compounds and medicinal use thereof

Publications (1)

Publication Number Publication Date
UA76969C2 true UA76969C2 (en) 2006-10-16

Family

ID=18837660

Family Applications (1)

Application Number Title Priority Date Filing Date
UA2003055026A UA76969C2 (en) 2000-12-01 2001-11-29 Lactams and their pharmaceutical use

Country Status (26)

Country Link
US (3) US7153850B2 (cs)
EP (1) EP1346993B1 (cs)
JP (2) JP3826400B2 (cs)
KR (1) KR100826818B1 (cs)
CN (2) CN100577651C (cs)
AT (1) ATE446297T1 (cs)
AU (3) AU2002218502B2 (cs)
BG (1) BG107857A (cs)
BR (1) BR0115852A (cs)
CA (1) CA2430124C (cs)
CZ (1) CZ20031520A3 (cs)
DE (1) DE60140270D1 (cs)
ES (1) ES2331299T3 (cs)
HU (1) HUP0400806A3 (cs)
IL (1) IL156158A0 (cs)
MX (1) MXPA03004876A (cs)
NO (1) NO325401B1 (cs)
NZ (1) NZ526164A (cs)
PL (1) PL362835A1 (cs)
RU (1) RU2287530C2 (cs)
SK (1) SK6582003A3 (cs)
TW (1) TWI241302B (cs)
UA (1) UA76969C2 (cs)
WO (1) WO2002044180A1 (cs)
YU (1) YU42603A (cs)
ZA (1) ZA200304100B (cs)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
YU42603A (sh) * 2000-12-01 2006-03-03 Ajinomoto Co.Inc. Laktamska jedinjenja i njihova farmaceutska primena
BRPI0407303A (pt) * 2003-02-07 2006-02-07 Ajinomoto Kk Composição farmacêutica
EP1683798B1 (en) 2003-10-31 2016-04-20 Ajinomoto Co., Inc. Fused polycyclic compounds having heterocycle and medicinal use thereof
EP1707567A4 (en) 2004-01-14 2009-08-19 Ajinomoto Kk NEW FUSED CYCLE COMPOUND
PL1802625T3 (pl) * 2004-10-13 2008-12-31 Hoffmann La Roche Dwupodstawione pirazolobenzodiazepiny użyteczne jako inhibitory CDK2 i angiogenezy oraz w leczeniu raka sutka, okrężnicy, płuca i gruczołu krokowego
NZ563131A (en) 2005-04-28 2010-09-30 Ajinomoto Kk Tricyclic lactam compound as a hypoglycemic agent
WO2008126920A1 (ja) 2007-04-11 2008-10-23 Ajinomoto Co., Inc. 糖尿病治療薬
WO2008139574A1 (ja) * 2007-04-27 2008-11-20 Ajinomoto Co., Inc. ラクタム化合物の結晶形およびその製造方法
WO2008139575A1 (ja) * 2007-04-27 2008-11-20 Ajinomoto Co., Inc. 経口投与用製剤
WO2008136394A1 (ja) * 2007-04-27 2008-11-13 Ajinomoto Co., Inc. ラクタム化合物の製造方法及びその製造中間体
CN101619041B (zh) * 2008-07-02 2012-07-04 重庆华邦制药股份有限公司 一种二酮基含氮环化合物的合成方法及其中间体
JP2012180283A (ja) * 2009-07-02 2012-09-20 Ajinomoto Co Inc ラクタム化合物の製造方法およびその製造中間体
JP2012180282A (ja) * 2009-07-02 2012-09-20 Ajinomoto Co Inc ラクタム化合物の製造方法およびその製造中間体
CN107106572B (zh) * 2014-12-22 2021-01-12 Ea制药株式会社 角膜上皮障碍治疗剂
EP3405183A4 (en) 2016-01-18 2019-12-11 Arisan Therapeutics Inc. ADAMATE DERIVATIVES FOR TREATING A FILOVIRUS INFECTION
US11548893B2 (en) 2017-07-15 2023-01-10 Arisan Therapeutics Inc. Enantiomerically pure adamantane carboxamides for the treatment of filovirus infection
AU2020210983B2 (en) * 2019-01-23 2024-05-16 Glycolysis Biomed Co., Ltd Beta-lactam compounds or salts thereof for use in long-acting prevention or treatment of a glucose metabolism disorder

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US48847A (en) * 1865-07-18 Improvement in vessels for reception and transportation of night-soil
US189597A (en) * 1877-04-17 Improvement in portable wash-stands
GB8720414D0 (en) * 1987-08-28 1987-10-07 Roussel Lab Ltd Chemical compounds
US5719296A (en) * 1995-10-30 1998-02-17 Merck & Co., Inc. Pseudopeptide lactam inhibitors of peptide binding to MHC class II proteins
JP2001512120A (ja) 1997-07-30 2001-08-21 アメリカン・ホーム・プロダクツ・コーポレイション 三環系バソプレシンアゴニスト
JP4204657B2 (ja) * 1997-12-05 2009-01-07 有限会社ケムフィズ 糖尿病の予防・治療剤
YU42603A (sh) * 2000-12-01 2006-03-03 Ajinomoto Co.Inc. Laktamska jedinjenja i njihova farmaceutska primena
BRPI0407303A (pt) 2003-02-07 2006-02-07 Ajinomoto Kk Composição farmacêutica

Also Published As

Publication number Publication date
CN1487940A (zh) 2004-04-07
TWI241302B (en) 2005-10-11
KR20030051893A (ko) 2003-06-25
NO325401B1 (no) 2008-04-21
AU2006241377A1 (en) 2006-12-14
BR0115852A (pt) 2003-12-23
US7632830B2 (en) 2009-12-15
CA2430124A1 (en) 2002-06-06
NZ526164A (en) 2004-09-24
US7326701B2 (en) 2008-02-05
CZ20031520A3 (cs) 2003-10-15
SK6582003A3 (en) 2003-09-11
US7153850B2 (en) 2006-12-26
JP2006213732A (ja) 2006-08-17
NO20032439D0 (no) 2003-05-28
AU1850202A (en) 2002-06-11
ATE446297T1 (de) 2009-11-15
RU2287530C2 (ru) 2006-11-20
EP1346993B1 (en) 2009-10-21
US20080096862A1 (en) 2008-04-24
US20060189597A1 (en) 2006-08-24
CA2430124C (en) 2011-01-11
ZA200304100B (en) 2004-08-22
JPWO2002044180A1 (ja) 2004-04-02
HUP0400806A3 (en) 2007-11-28
PL362835A1 (en) 2004-11-02
ES2331299T3 (es) 2009-12-29
DE60140270D1 (de) 2009-12-03
WO2002044180A1 (en) 2002-06-06
CN1269818C (zh) 2006-08-16
JP3826400B2 (ja) 2006-09-27
EP1346993A4 (en) 2005-12-21
AU2006241377B2 (en) 2009-01-08
CN100577651C (zh) 2010-01-06
JP4505753B2 (ja) 2010-07-21
KR100826818B1 (ko) 2008-05-02
HUP0400806A2 (hu) 2004-07-28
AU2002218502B2 (en) 2006-09-21
BG107857A (bg) 2004-06-30
MXPA03004876A (es) 2004-01-27
EP1346993A1 (en) 2003-09-24
NO20032439L (no) 2003-07-18
US20040048847A1 (en) 2004-03-11
CN1911915A (zh) 2007-02-14
YU42603A (sh) 2006-03-03
IL156158A0 (en) 2003-12-23

Similar Documents

Publication Publication Date Title
UA76969C2 (en) Lactams and their pharmaceutical use
EP3307262B1 (en) Compounds for use in treating neuromuscular disorders
TW215055B (cs)
EP3517538A1 (en) Pyrazolopyridine derivative having glp-1 receptor agonist effect
KR20220082092A (ko) 화합물
UA75660C2 (en) Triamide-substituted indoles, benzofuranes and benzothiophenes as inhibitors of microsomal triglyceride transfer protein (mtp) and/or apolipoprotein b (apo b) secretion
EP3615019B1 (en) Modulator of sestrin-gator2 interaction for use in the treatment of treatment-resistant depression
EP3150592B1 (en) Alk kinase inhibitor, and preparation method and use thereof
TW201028380A (en) C5aR antagonists
UA57811C2 (uk) Фармацевтична композиція, що містить інгібітор альдозоредуктази та інгібітор глікогенфосфорилази (варіанти), комплект, який її включає, та способи лікування ссавців зі станом інсулінорезистентності
JP2025010154A (ja) 線維症及び炎症の処置のための組成物
KR20120087878A (ko) 1,3-프로판디설포닉 애시드의 수송을 위한 방법, 화합물 및 조성물
WO2012118562A1 (en) Compositions and methods for treating depression, adhd and other central nervous system disorders employing novel bupropion compounds, and methods for production and use of novel bupropion compounds and formulations
ES2910049T3 (es) Moduladores heterocíclicos de la síntesis de lípidos
CA3019091C (en) Medicament
JPH02503794A (ja) アルツハイマー病の治療のための化合物
CN116120314A (zh) 用于调节毛发生长的组合物和方法
RU2233278C2 (ru) Пиримидиновые соединения, способ их получения и фармацевтическая композиция
HUP0202938A2 (hu) N-aril-2-(szulfonil-amino)-benzamidok mint foszfát-transzport inhibitorok és ezeket tartalmazó gyógyszerkészítmények
WO2020007322A1 (zh) 一种靶向降解bet蛋白的化合物及其应用
TW200304817A (en) Chemical compounds
US20250090530A1 (en) Combinations for the treatment of cancer
SA95160293B1 (ar) مشتقات حمض اميني حلقي cyclic amiono acid لها نشاط تثبيط انزيم ACE وNEP
US20250352513A2 (en) Salts of c4-carboxylic acid- and c4-carbonothioate-substituted tryptamine derivatives and methods of using
TW200940543A (en) Maleate, besylate and L-malate salts of 6-(5-chloro-2-pyridyl)-5-[(4-methyl-1-piperazinyl)carbonyloxy]-7-oxo-6,7-dihydro-5H-pyrrolo[3,4-b]pyrazine